EZH2 is overexpressed in laryngeal squamous cell carcinoma and enhances the stem-like properties of AMC-HN-8 cells

Oncology Letters

Volumn 12, Issue 2, 2016, Pages 837-846

  Huang, Jiameng ^a   Zhou, Liang ^a   Chen, Hui ^a   Wu, Chunping ^a   Duo, Zhang ^a   Zhang, Yanping ^a  

^a EYE AND ENT HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

AMC HN 8 cell line; Enhancer of zeste 2 polycomb repressive complex 2 subunit; Expression; Laryngeal squamous cell carcinoma; Stem like properties

Indexed keywords

CISPLATIN; LENTIVIRUS VECTOR; MESSENGER RNA; TRANSCRIPTION FACTOR EZH2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENICITY; CELL CYCLE ASSAY; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNGEAL CANCER CELL LINE; LARYNX SQUAMOUS CELL CARCINOMA; MALE; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; WESTERN BLOTTING;

EID: 84977071075     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2016.4704     Document Type: Article

References (37)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Simon JA and Lange CA: Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 647: 21-29, 2008.
3. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden JM, et al: The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439: 871-874, 2006.
4. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, et al: Control of developmental regulators by polycomb in human embryonic stem cells. Cell 125: 301-313, 2006.
5. Ezhkova E, Pasolli HA, Parker JS, Stokes N, Su IH, Hannon G, Tarakhovsky A and Fuchs E: Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. Cell 136: 1122-1135, 2009.
6. Li KQ, Liu C, Zhou BF, Bi L, Huang H, Lin T and Xu K: Role of EZH2 in the growth of prostate cancer stem cells isolated from LNCaP cells. Int J Mol Sci 14: 11981-11993, 2013.
7. Rizzo S, Hersey JM, Mellor P, Dai W, Santos-Silva A, Liber D, Luk L, Titley I, Carden CP, Box G, Hudson DL, Kaye SB and Brown R: Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther. 10: 325-335, 2011.
8. Sobin LH, Gospodarowicz MK and Wittekind C: UICC TNM classification of malignant tumours. 7th edition. Wiley-Blackwell; Oxford: pp. 63-72. 2009
9. Shi Y, Gong HL, Zhou L, Tian J and Wang Y: CD24: A novel cancer biomarker in laryngeal squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec 74: 78-85, 2012.
10. Zhao LB, Yu Y, Wu J, Bai J, Zhao Y, Li C, Sun W and Wang X: Role of EZH2 in oral squamous cell carcinoma carcinogenesis. Gene 537: 197-202, 2014.
11. Blake JL, Runhua S, Vikas M, Glenn M, Federico A and Cherie-Ann ON: Improvements in survival and disparities for advanced-staged laryngeal cancer. JAMA Otolaryngol Head Neck Surg 141: 169-173, 2015.
12. Kamminga LM, Bystrykh LV, de Boer A, Houwer S, Douma J, Weersing E, Dontje B and de Haan G: The polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood 107: 2170-2179, 2006.
13. Juan AH, Derfoul A, Feng X, Ryall JG, Dell’Orso S, Pasut A, Zare H, Simone JM, Rudnicki MA and Sartorelli V: Polycomb EZH2 controls self-renewal and safeguards the transcriptional identity of skeletal muscle stem cells. Gene Dev 25: 789-794, 2011.
14. Sher F, Rössler R, Brouwer N, Balasubramaniyan V, Boddeke E and Copray S: Differentiation of neural stem cells into oligodendrocytes: Involvement of the polycomb group protein Ezh2. Stem Cells 26: 2875-2883, 2008.
15. Gong Y, Huo L, Liu P, Sneige N, Sun X, Ueno NT, Lucci A, Buchholz TA, Valero V and Cristofanilli M: Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer 117: 5476-5484, 2011.
16. Wan L, Li X, Shen H and Bai X: Quantitative analysis of EZH2 expression and its correlations with lung cancer patients’ clinical pathological characteristics. Clin Transl Oncol 15: 132-138, 2013.
17. Wagener N, Macher-Goeppinger S, Pritsch M, Hüsing J, Hoppe-Seyler K, Schirmacher P, Pfitzenmaier J, Haferkamp A, Hoppe-Seyler F and Hohenfellner M: Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. Bmc Cancer 10: 524, 2010.
18. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP, et al: EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate and breast. J Clin Oncol 24: 268-273, 2006.
19. Kidani K, Osaki M, Tamura T, Yamaga K, Shomori K, Ryoke K and Ito H: High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. Oral Oncol 45: 39-46, 2009.
20. Alajez NM, Shi W, Hui AB, Bruce J, Lenarduzzi M, Ito E, Yue S, O’Sullivan B and Liu F: Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101 and miR-98. Cell Death Dis 1: e85, 2010.
21. Rao ZY, Cai MY, Yang GF, He LR, Mai SJ, Hua WF, Liao YJ, Deng HX, Chen YC, Guan XY, et al: EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis 31: 1576-1583, 2010.
22. Tong ZT, Cai MY, Wang XG, Kong LL, Mai SJ, Liu YH, Zhang HB, Liao YJ, Zheng F, Zhu W, et al: EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin. Oncogene 31: 583-594, 2012.
23. Crea F, Fornaro L, Bocci G, Sun L, Farrar WL, Falcone A and Danesi R: EZH2 inhibition: Targeting the crossroad of tumor invasion and angiogenesis. Cancer Metast Rev 31: 753-761, 2012.
24. Chen H, Zhou L, Wan G, Dou T and Tian J: BMI1 promotes the progression of laryngeal squamous cell carcinoma. Oral Oncol 47: 472-481, 2011.
25. Suvà ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC, Baumer K, Le Bitoux MA, Marino D, Cironi L, et al: EZH2 Is Essential for glioblastoma cancer stem cell maintenance. Cancer Res 69: 9211-9218, 2009.
26. Majewski IJ, Blewitt ME, de Graaf CA, McManus EJ, Bahlo M, Hilton AA, Hyland CD, Smyth GK, Corbin JE, Metcalf D, et al: Polycomb repressive complex 2 (PRC2) restricts hematopoietic stem cell activity. PLoS Biol 6: e93, 2008.
27. van Vlerken LE, Kiefer CM, Morehouse C, Li Y, Groves C, Wilson SD, Yao Y, Hollingsworth RE and Hurt EM: EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter. Stem Cells Transl Med 2: 43-52, 2013.
28. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A III, Diaz E, et al: EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492: 108-112, 2012.
29. Sasaki H, Setoguchi T, Matsunoshita Y, Gao H, Hirotsu M and Komiya S: The knock-down of overexpressed EZH2 and BMI-1 does not prevent osteosarcoma growth. Oncol Rep 23: 677-684, 2010.
30. Wu Z, Lee ST, Qiao Y, Li Z, Lee PL, Lee YJ, Jiang X, Tan J, Aau M, Lim CZ and Yu Q: Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage. Cell Death Differ 18: 1771-1779, 2011.
31. Zhang Q, Padi SK, Tindall DJ and Guo B: Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31. Cell Death Dis 5: e1486, 2014.
32. Serguei V and Xin W: Cancer stem cells and drug resistance: The potential of nanomedicine. Nanomedicine 7: 597-615, 2012.
33. Hu S, Yu L, Li Z, Shen Y, Wang J, Cai J, Xiao L and Wang Z: Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther 10: 788-795, 2010.
34. Meng X, Huang Z, Wang R, Jiao Y, Li H, Xu X, Feng R, Zhu K, Jiang S, Yan H and Yu J: The prognostic role of EZH2 expression in rectal cancer patients treated with neoadjuvant chemoradiotherapy. Radiat Oncol 9: 188, 2014.
35. Lu CH, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, et al: Regulation of tumor angiogenesis by EZH2. Cancer Cell 18: 185-197, 2010.
36. Benetatos L, Voulgaris E, Vartholomatos G and Hatzimichael E: Non-coding RNAs and EZH2 interactions in cancer: Long and short tales from the transcriptome. Int J Cancer 133: 267-274, 2013.
37. Chen H, Xin Y, Zhou L, Huang JM, Tao L, Cheng L and Tian J: Cisplatin and paclitaxel target significant long noncoding RNAs in laryngeal squamous cell carcinoma. Med Oncol 31: 246, 2014.